Full Text | PDF

Share on tweeters Share on facebook Share on linkedin Share on googleplus

J Cancer 2019; 10(2):416-417. doi:10.7150/jca.29461 This issue Cite

Letter To The Editor

Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer

Guoxing Wan✉, Fengjun Cao, Xuanbin Wang, Xue Sun

Department of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan 442000, China.

✉ Corresponding author: Guoxing Wan, MD, PhD, Department of Oncology, Renmin Hospital, Hubei University of Medicine, 39 Chaoyang Road, 442000 Shiyan, China. Phone: +86-719-8637385; Fax: +86-719-8637385; Email: 15gxwanedu.cn

Citation:
Wan G, Cao F, Wang X, Sun X. Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer. J Cancer 2019; 10(2):416-417. doi:10.7150/jca.29461. https://www.jcancer.org/v10p0416.htm
Other styles

File import instruction

Citation styles

APA
Wan, G., Cao, F., Wang, X., Sun, X. (2019). Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer. Journal of Cancer, 10(2), 416-417. https://doi.org/10.7150/jca.29461.

ACS
Wan, G.; Cao, F.; Wang, X.; Sun, X. Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer. J. Cancer 2019, 10 (2), 416-417. DOI: 10.7150/jca.29461.

NLM
Wan G, Cao F, Wang X, Sun X. Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer. J Cancer 2019; 10(2):416-417. doi:10.7150/jca.29461. https://www.jcancer.org/v10p0416.htm

CSE
Wan G, Cao F, Wang X, Sun X. 2019. Bevacizumab Added to Neoadjuvant Chemotherapy in HER2-Negative Non-Metastatic Breast Cancer. J Cancer. 10(2):416-417.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image

©2024 Ivyspring International Publisher. Terms of use